Compare BridgeBio Pharma Inc (BBIO) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Kraft Heinz Co — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Kraft Heinz Co trades at $24.68 (market cap $29.23B). The key difference: Kraft Heinz Co is the larger of the two by market cap, and Kraft Heinz Co pays a 6.49% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KHC | |
|---|---|---|
Market Cap | $16.36B | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $28.06 |
52-Week Low | $47.29 | $21.21 |
Enterprise Value | $18.14B | $45.55B |
Dividend Yield | — | 6.49% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
